Literature DB >> 10471595

Comparison of two methods of diagnostic lung lavage in ventilated infants with lung disease.

P A Dargaville1, M South, P N McDougall.   

Abstract

The methods of nonbronchoscopic lung lavage used for collection of samples of epithelial lining fluid (ELF) in intubated patients are poorly standardized and incompletely validated. In infants with lung disease requiring ventilatory support, we evaluated two techniques of small volume saline lavage for the collection of a specimen suitable for pulmonary surfactant analysis. We aimed to compare apparent origin of the return fluid obtained by each method, equivalence and agreement of the estimates of measured pulmonary surfactant concentration, and the relative strength of association between surfactant indices and lung dysfunction. Fifty-three contemporaneous paired samples of lung lavage fluid suitable for surfactant analysis were collected from 31 infants using tracheal aspirate (TA, 4 x 0.5 ml saline), and then nonbronchoscopic bronchoalveolar lavage (NB-BAL, 3 x 1 ml/kg). Return fluid from TA had higher mean ELF concentration of total protein and IgA secretory component (SC), and a lower surfactant protein A (SP-A) concentration than NB-BAL, indicating that the TA lavage was sampling ELF more proximally in the tracheobronchial tree (protein: TA 7.7 versus NB-BAL 4.7 mg/ml; SC: 21 versus 1.8 microgram/ml; SP-A: 9.8 versus 19 microgram/ml; all p < 0.01). Mean concentration of surfactant indices in ELF differed only for SP-A, but for all indices, paired values showed poor agreement on Bland-Altman analysis, highlighting the potential imprecision associated with small volume lung lavage. TA return fluid yielded estimates of surfactant indices which were at least equivalent to NB-BAL in prediction of the severity of lung dysfunction. We conclude that NB-BAL return fluid has more distal origin, but analysis of TA fluid may have equal validity in the estimation of indices of pulmonary surfactant. The results of individual estimates of ELF constituents in a single sample of lavage fluid should be interpreted with caution, even when standardized sampling techniques are employed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471595     DOI: 10.1164/ajrccm.160.3.9811048

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  6 in total

Review 1.  Surfactant therapy for meconium aspiration syndrome: current status.

Authors:  Peter A Dargaville; John F Mills
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Role of distinct phospholipases A2 and their modulators in meconium aspiration syndrome in human neonates.

Authors:  Daniele De Luca; Angelo Minucci; Domenico Tripodi; Marco Piastra; Domenico Pietrini; Cecilia Zuppi; Giorgio Conti; Virgilio P Carnielli; Ettore Capoluongo
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

3.  Reduced platelet-derived growth factor receptor expression is a primary feature of human bronchopulmonary dysplasia.

Authors:  Antonia P Popova; J Kelley Bentley; Tracy X Cui; Michelle N Richardson; Marisa J Linn; Jing Lei; Qiang Chen; Adam M Goldsmith; Gloria S Pryhuber; Marc B Hershenson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-06       Impact factor: 5.464

Review 4.  Biomarkers in pediatric acute respiratory distress syndrome.

Authors:  Erin F Carlton; Heidi R Flori
Journal:  Ann Transl Med       Date:  2019-10

5.  Isolation of tracheal aspirate mesenchymal stromal cells predicts bronchopulmonary dysplasia.

Authors:  Antonia P Popova; Paul D Bozyk; J Kelley Bentley; Marisa J Linn; Adam M Goldsmith; Robert E Schumacher; Gary M Weiner; Amy G Filbrun; Marc B Hershenson
Journal:  Pediatrics       Date:  2010-10-11       Impact factor: 7.124

6.  Controlled hypothermia may improve surfactant function in asphyxiated neonates with or without meconium aspiration syndrome.

Authors:  Chiara Autilio; Mercedes Echaide; Daniele De Luca; Jesús Pérez-Gil
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.